SCHEMBL7180124

SCHEMBL7180124

CCc1cccc(CC)c1C(=O)c1ccccc1[P](=O)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 3/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR2 P34972 8/20 0.33
SHBG P04278 1/20 0.33
CNR1 P21554 3/20 0.32
NR1I2 O75469 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
CLCN2 P51788 1/20 0.32
CRHR1 P34998 1/20 0.32
BCL2L1 Q07817 1/20 0.32
F2R P25116 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188217 0.91 HPGD (0.35) MEN1KMT2AHPGDSMN1; SMN2CNR2
SCHEMBL7182661 0.88 SHBG (0.32) MEN1KMT2AHPGDCNR2SHBG
SCHEMBL7180500 0.87 KMT2A (0.39) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL7183573 0.87 KMT2A (0.39) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL7187205 0.84 KMT2A (0.39) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL7181110 0.84 MEN1 (0.47) MEN1KMT2ALMNACNR2CNR1
SCHEMBL7184426 0.84 MEN1 (0.36) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL7175433 0.83 KCNK3 (0.39) MEN1KMT2ALMNAHPGDCNR2
SCHEMBL7188528 0.83 KMT2A (0.38) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL7174639 0.82 MEN1 (0.37) MEN1KMT2ALMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885KMT2A 1586/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885KMT2A 956/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.